Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 6/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.40 |
| ▸ | CDK2 | P24941 | 9/20 | 0.40 |
| ▸ | GSK3B | P49841 | 7/20 | 0.40 |
| ▸ | ELOC | Q15369 | 3/20 | 0.40 |
| ▸ | ELOB | Q15370 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30705637 | 0.88 | VHL (0.51) | VHLCCNE1CDK2GSK3BELOC | |
| SCHEMBL30705671 | 0.86 | VHL (0.39) | VHLP2RX7EPHX2 | |
| SCHEMBL21696618 | 0.76 | VHL (0.53) | VHLCCNE1CDK2GSK3BPOLB | |
| SCHEMBL30705635 | 0.75 | VHL (0.38) | VHLP2RX7EPHX2 | |
| SCHEMBL30705631 | 0.73 | RXRA (0.34) | — | |
| SCHEMBL32661830 | 0.72 | VHL (0.51) | VHLCCNE1CDK2GSK3BELOC | |
| SCHEMBL8248147 | 0.72 | MMP2 (0.33) | — | |
| SCHEMBL24014601 | 0.70 | FUCA1 (0.32) | — | |
| SCHEMBL25757863 | 0.70 | FUCA1 (0.32) | — | |
| SCHEMBL29624408 | 0.70 | MMP2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4539844-A2 | COMPOUNDS FOR TREATMENT OF A CORONAVIRUS INFECTION | Trawsfynydd Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119604290-A | Compounds for the treatment of coronavirus infections | 特劳斯芬尼德治疗股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2023245166-A2 | COMPOUNDS FOR TREATMENT OF A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | VHL 1899/4885CCNE1 1826/4885CDK2 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.